NSB — Neuroscientific Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- AU$49.89m
- AU$42.62m
- AU$0.17m
- 20
- 28
- 73
- 33
Annual cashflow statement for Neuroscientific Biopharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.028 | 0.068 | 0.108 | 0.135 | 0.184 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.6 | -6.94 | -2.3 | 0.044 | -0.941 |
| Capital Expenditures | -0.03 | -0.004 | 0 | -0.002 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | -0.036 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | -0.03 | -0.004 | 0 | -0.002 | -0.036 |
| Financing Cash Flow Items | — | — | — | — | -0.215 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 13.5 | 0 | 0 | — | 3.29 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 10.9 | -6.95 | -2.3 | 0.042 | 2.31 |